ESC2 Antibody

What is ESC2/ESCO2 and what molecular functions does it perform?

ESC2 (Establishment of Silent Chromatin 2) encodes a protein with two tandem C-terminal SUMO-like domains (SD1 and SD2) and is highly conserved from yeasts to humans . In humans, the homologous protein is known as ESCO2. This protein plays multiple critical roles in maintaining genome integrity.

ESC2 was initially identified for its function in gene silencing, particularly at the HMR locus in yeast. Mechanistically, ESC2 interacts with Sir2 through its N-terminal domain, which is essential for its silencing function . Beyond gene silencing, ESC2 has been implicated in DNA damage tolerance (DDT) pathways. Cells lacking ESC2 (esc2Δ) show sensitivity to DNA damaging agents such as hydroxyurea (HU) and methyl-methane sulphonate (MMS), exhibit defects in sister chromatid cohesion, and have a reduced lifespan .

At the molecular level, ESC2 has a two-faceted role in recombination-mediated DDT: an early role in promoting recombination-mediated damage-bypass by limiting Rad51-dismantling by Srs2, and a later role in the metabolism of sister chromatid junctions (SCJs) . ESC2 also specifically interacts with the Mus81 complex via its SUMO-like domains and stimulates its enzymatic activity, contributing to the resolution of recombination intermediates .

What are the key structural features of ESC2 that researchers should consider when selecting antibodies?

When selecting antibodies against ESC2/ESCO2, researchers should consider the protein's domain organization, which directly impacts epitope availability and antibody specificity. ESC2 has distinct functional domains:

For effective antibody selection, researchers should determine which domain they wish to target based on their specific research questions. For instance, antibodies targeting the N-terminal domain would be appropriate for studying Sir2 interactions and gene silencing functions, while antibodies against the SUMO-like domains would be more suitable for investigating interactions with the Mus81 complex and SCJ resolution.

Importantly, research has shown that deletion of the C-terminal domain (Esc2ΔC) makes the protein intrinsically unstable, while the presence of even one SUMO-like domain is sufficient to stabilize the protein . This information is critical when selecting antibodies for detecting truncated or mutant forms of ESC2.

What validation methods should be employed to ensure ESC2 antibody specificity?

Ensuring antibody specificity is crucial for obtaining reliable research data. For ESC2/ESCO2 antibodies, comprehensive validation should include:

• Western Blot Analysis: The primary method for validation, ideally comparing wild-type samples with esc2Δ/ESCO2 knockout samples. Prior research indicates that wild-type ESC2 and its derivatives show similar expression levels, except for Esc2ΔC, which is unstable and weakly detected . Researchers should be aware that some ESC2 fragments might show altered mobility patterns due to charged amino acids in the N-terminal domain.

• Immunoprecipitation (IP): Functional validation through IP can confirm the antibody's ability to recognize the native protein. Research shows that while some ESC2 truncation mutants may be unstable in crude extracts, they can be detected in immunoprecipitates . This suggests that enrichment through IP may be necessary for detecting certain ESC2 variants.

• Immunohistochemistry (IHC) and Immunocytochemistry (ICC): These methods validate antibody performance in preserved tissue or cellular contexts. High-quality antibodies, such as those from Atlas Antibodies, undergo validation in IHC, ICC-IF, and WB applications .

• Enhanced Validation: Advanced techniques including siRNA knockdown, overexpression systems, orthogonal validation (comparing results with alternative antibodies), and independent antibody validation (using antibodies targeting different epitopes) provide additional confidence in antibody specificity .

• Recombinant Protein Controls: Using purified recombinant ESC2 protein (full-length and fragments) as positive controls, as described in research protocols where GST-tagged ESC2 fragments were purified and characterized .

How can ESC2 antibodies be utilized to investigate DNA damage repair mechanisms?

ESC2 antibodies serve as powerful tools for investigating DNA damage repair mechanisms, particularly those involving recombination-mediated DNA damage tolerance (DDT) pathways. Based on current research, here are methodological approaches for such investigations:

• Chromatin Immunoprecipitation (ChIP): ESC2 antibodies can be used to track the recruitment of ESC2 to sites of DNA damage, particularly to stalled replication forks or sister chromatid junctions (SCJs). Research has shown that ESC2 preferentially binds to Holliday junction structures with high affinity (~80% binding at 125 nM), making ChIP an excellent approach for studying its localization during DNA damage response .

• Co-immunoprecipitation for Protein Interaction Studies: ESC2 antibodies can help identify proteins that interact with ESC2 during the DNA damage response. Previous studies have demonstrated that ESC2 directly interacts with the Mus81 complex through its SUMO-like domains, independent of DNA mediation (as confirmed by ethidium bromide treatment not affecting this interaction) . Researchers can use pull-down assays with ESC2 antibodies to investigate these and other potential interactions under various damage conditions.

• Cell Cycle-Specific Analysis: Since the activity of the Mus81 complex is cell cycle-regulated, with peak activity in G2/M, ESC2 antibodies can be used to study the dynamics of ESC2-Mus81 interactions throughout the cell cycle. Research indicates that ESC2 interacts with the Mus81 complex regardless of cell cycle stage or phosphorylation status of the Mms4 protein .

• In situ Resolution Assays: ESC2 antibodies can be employed to visualize the localization and dynamics of ESC2 during the resolution of DNA damage, particularly in relation to other repair factors. This approach can help determine the temporal and spatial relationships between ESC2 and other repair proteins during the resolution of SCJs.

• Biochemical Activity Assays: When combined with purified recombinant ESC2 and Mus81 complex, antibodies can be used to assess how ESC2 stimulates the endonuclease activity of the Mus81 complex on various DNA substrates, particularly those representing recombination intermediates.

What methodological approaches can resolve contradictory findings when using ESC2 antibodies?

When researchers encounter contradictory findings using ESC2 antibodies, several methodological approaches can help resolve these discrepancies:

• Epitope Mapping and Antibody Selection: Different antibodies targeting different epitopes of ESC2 may yield varying results due to epitope accessibility in different experimental contexts. Research has shown that the N-terminal and C-terminal domains of ESC2 have distinct functional roles . Therefore, using multiple antibodies targeting different regions (N-terminal DNA binding domain vs. C-terminal SUMO-like domains) can provide a more comprehensive understanding of ESC2 behavior in different contexts.

• Protein Stability Considerations: Studies indicate that certain ESC2 truncations, particularly Esc2ΔC, are intrinsically unstable and difficult to detect in crude extracts, while others maintain normal expression levels . When contradictory findings arise, researchers should consider whether protein stability issues might be contributing factors and adjust experimental approaches accordingly (e.g., using immunoprecipitation to enrich the protein).

• Protein Complex Integrity Assessment: Since ESC2 functions in complex with other proteins like the Mus81 complex, contradictory findings might stem from differences in complex integrity across experimental conditions. In vitro pull-down assays using purified components, as demonstrated in previous research , can help determine whether contradictions arise from differences in complex formation.

• Structural Analysis of Protein Fragments: Circular dichroism analysis has revealed that different ESC2 fragments show distinct structural characteristics. For instance, the Esc2 1-199 fragment exhibits a poly-l-proline-II type (PPII) helix spectrum, unlike the prominent α-helices seen in wild-type ESC2 . Such structural differences could impact antibody recognition and experimental outcomes.

• DNA-Binding Activity Verification: Since ESC2 has DNA-binding capabilities that depend on specific regions (particularly AA154-198), contradictions might arise if this functionality is compromised in certain experimental settings. Conducting electrophoretic mobility-shift assay (EMSA) with purified components, as described in previous research , can help determine whether DNA-binding activity is consistent across experimental conditions.

How does the presence of SUMO-like domains in ESC2 affect antibody-based detection in different experimental conditions?

The SUMO-like domains (SLDs) in ESC2 present unique considerations for antibody-based detection across different experimental conditions:

What are the experimental considerations when studying ESC2's role in sister chromatid cohesion?

When investigating ESC2's role in sister chromatid cohesion, researchers should consider several experimental approaches and potential challenges:

• Phenotypic Analysis of Mutants: Research has established that esc2Δ cells exhibit defects in sister chromatid cohesion . When designing experiments to study this phenotype, researchers should consider:

  • Using synchronized cell populations, as cohesion defects may be cell-cycle specific

  • Implementing genetic approaches that combine esc2Δ with mutations in other cohesion-related genes (e.g., the enhancement of phenotypes observed in esc2Δ rrm3Δ double mutants)

  • Employing direct visualization methods such as fluorescent repressor-operator systems to monitor cohesion in living cells

• Domain-Specific Function Analysis: Different domains of ESC2 contribute differently to its functions. For cohesion studies, researchers should consider creating and analyzing domain-specific mutants. Previous research has characterized several truncation mutants:

  • Esc2ΔN (lacking the N-terminal domain) fails to interact with Sir2

  • Esc2ΔC (lacking both SUMO-like domains) is unstable but can still interact with Sir2

  • Esc2 truncation mutants lacking either SD1 or SD2 maintain silencing function, while mutants lacking both domains show silencing defects

• Antibody Selection for Chromatin Association Studies: When studying ESC2's association with chromatin during sister chromatid cohesion, antibody selection is critical. Researchers should:

  • Choose antibodies that recognize epitopes not involved in chromatin binding

  • Consider that the DNA binding region of ESC2 (approximately AA154-198) shows high affinity for junction structures

  • Be aware that the N-terminal region (AA1-199) binds DNA with different structural characteristics than the full-length protein

• Interaction with DNA Damage Response Pathways: ESC2's role in cohesion is linked to its function in DNA damage tolerance. Experimental designs should:

  • Include conditions that induce DNA damage (e.g., treatment with hydroxyurea or methyl-methane sulphonate)

  • Consider the interconnection between cohesion defects and DNA damage accumulation (research shows esc2Δ rrm3Δ cells accumulate DNA damage in late S/G2)

  • Implement methods to measure both cohesion defects and DNA damage markers simultaneously

• Cell Cycle Considerations: Since sister chromatid cohesion is established during S phase and maintained until anaphase, experimental designs should incorporate cell cycle analysis:

  • Use synchronized cell populations to study ESC2 function at specific cell cycle stages

  • Consider that interactions between ESC2 and other proteins (like the Mus81 complex) occur regardless of cell cycle stage

  • Implement flow cytometry or other methods to correlate cohesion phenotypes with cell cycle position

How can researchers optimize protocols for studying ESC2's DNA binding properties?

Optimizing protocols for studying ESC2's DNA binding properties requires careful consideration of protein preparation, substrate selection, and assay conditions based on the current research findings:

• Protein Purification Considerations:

  • Expression System Selection: Previous research successfully utilized E. coli for expressing GST-tagged ESC2 and its fragments . For optimal results, researchers should consider using expression vectors like pGEX6-P1 with a PreScission protease cleavage site between GST and ESC2.

  • Purification Strategy: A multi-step purification process is recommended, including:

    • Initial purification using glutathione-sepharose beads

    • Secondary purification using ion-exchange chromatography (Mono Q column)

    • Optional protease treatment to remove the GST tag when needed

  • Buffer Optimization: Research has utilized buffer T (20 mM Tris-HCl, 100 mM KCl, 1 mM DTT, 0.5 mM EDTA, and 0.01% Nonidet P-40; pH 7.5) for protein storage and binding assays . Researchers should verify protein stability in their chosen buffers through thermal shift assays or circular dichroism.

• DNA Substrate Selection and Preparation:

  • Substrate Diversity: Research has demonstrated that ESC2 has differential binding affinities for various DNA structures, with highest affinity for Holliday junctions (HJs) and nicked Holliday junctions (nHJs) . When studying ESC2's DNA binding properties, researchers should prepare:

    • Simple substrates (ssDNA, dsDNA)

    • Replication intermediates (Y-form, 3' flap, 5' flap, Fork structures)

    • Recombination intermediates (HJ, nHJ)

  • Substrate Labeling: For detection in electrophoretic mobility-shift assays (EMSA), fluorescent labeling of DNA substrates is recommended, as used in previous studies .

• Binding Assay Optimization:

  • EMSA Protocol Refinement: Based on published methods, researchers should:

    • Incubate purified ESC2 (or fragments) with labeled substrates (7 nM) at 30°C in buffer D (40 mM Tris-HCl, 50 mM KCl, 1 mM dithiothreitol, 5 mM MgCl2; pH 7.5) for 10 minutes

    • Resolve reactions in 7.5% native polyacrylamide gels in 0.5xTBE buffer at 4°C

    • Visualize using appropriate imaging systems (e.g., Fuji FLA 9000 imager)

  • Protein Concentration Range: Published studies used protein concentrations of 16-1000 nM, with significant binding observed at concentrations as low as 125 nM for HJ structures . Researchers should use a wide concentration range to establish binding curves.

• Domain-Specific Analysis:

  • Truncation Mutant Design: When studying which domains are responsible for DNA binding, researchers should consider creating truncation mutants similar to those characterized in previous studies:

    • Esc2 1-199, Esc2 1-294, Esc2 1-374, Esc2 1-151

    • Esc2 200-456, Esc2 Δ154-198

  • Structural Verification: Circular dichroism analysis should be performed to ensure proper folding of truncated proteins, as previous research revealed different spectral characteristics for different fragments .

• Data Analysis and Quantification:

  • Binding Affinity Determination: Quantify the percentage of bound substrate at different protein concentrations to determine relative binding affinities.

  • Comparative Analysis: Always include wild-type ESC2 as a control when testing truncation mutants or when evaluating the effects of different experimental conditions.

What approaches should be considered when using ESC2 antibodies in chromatin immunoprecipitation experiments?

When performing chromatin immunoprecipitation (ChIP) experiments with ESC2 antibodies, researchers should implement several methodological considerations to ensure successful results:

• Antibody Selection Strategy:

  • Epitope Considerations: Since ESC2 contains distinct functional domains with different binding properties, antibody selection should be based on specific research questions. Research has shown that the DNA-binding region (approximately AA154-198) is crucial for binding to Holliday junctions , so antibodies targeting this region might be masked when ESC2 is bound to DNA.

  • Antibody Validation: Before ChIP experiments, antibodies should be validated in other applications (Western blot, immunoprecipitation) to confirm specificity. Commercial antibodies like those from Atlas Antibodies undergo validation in multiple applications .

  • Multiple Antibody Approach: Using antibodies targeting different epitopes of ESC2 can help validate ChIP results and overcome potential issues with epitope masking.

• Crosslinking Optimization:

  • Crosslinking Conditions: Since ESC2 has been shown to bind DNA structures with varying affinities (higher for junction structures than simple DNA) , optimization of formaldehyde crosslinking conditions is essential. Start with standard conditions (1% formaldehyde for 10 minutes) and adjust as needed.

  • Double Crosslinking: Consider implementing a double crosslinking approach (using both formaldehyde and protein-specific crosslinkers) to enhance detection of protein-protein interactions, particularly for studying ESC2's interactions with the Mus81 complex .

• Chromatin Preparation:

  • Sonication Parameters: Optimize sonication conditions to generate DNA fragments of appropriate size (200-500 bp). Consider that ESC2 preferentially binds to specific DNA structures, so excessive sonication might disrupt these structures and affect results.

  • Enzymatic Digestion Alternative: For studies focusing on ESC2's association with specific DNA structures like Holliday junctions, enzymatic digestion with MNase may be preferable to preserve these structures.

• Experimental Controls:

  • Input Control: Essential for normalization of ChIP signals.

  • Negative Controls: Include IgG controls and, when possible, chromatin from esc2Δ cells to establish background levels.

  • Positive Controls: Include ChIP for proteins known to co-localize with ESC2, such as components of the Mus81 complex .

  • Spike-in Controls: Consider using spike-in normalization with chromatin from a different species to control for technical variations.

• Data Analysis and Interpretation:

  • Peak Calling: When analyzing genome-wide ChIP-seq data for ESC2, consider its potential localization to specific genomic features like replication origins or sites of replication stress.

  • Integration with Other Datasets: Integrate ESC2 ChIP data with other relevant datasets, such as DNA damage markers, replication timing data, or ChIP data for interacting proteins like the Mus81 complex.

  • Cell Cycle Considerations: Since ESC2's functions in DNA damage tolerance and sister chromatid cohesion may be cell cycle-dependent, consider performing ChIP experiments in synchronized cell populations.

How can researchers effectively differentiate between ESC2 and ESCO2 in experimental systems?

Differentiating between ESC2 (primarily studied in yeast) and ESCO2 (its human homolog) requires careful experimental design and appropriate controls:

• Antibody Specificity Verification:

  • Sequence Alignment Analysis: Before selecting antibodies, perform sequence alignment between yeast ESC2 and human ESCO2 to identify regions of similarity and divergence. This information guides the selection of species-specific antibodies.

  • Cross-Reactivity Testing: When studying one organism, test for potential cross-reactivity of antibodies with homologs from other species. This is particularly important in experimental systems where both proteins might be present (e.g., humanized yeast models).

  • Knockout/Knockdown Controls: Include esc2Δ yeast strains or ESCO2 knockdown human cell lines as negative controls to confirm antibody specificity.

• Experimental System Selection:

  • Species-Appropriate Models: When studying ESC2 functions, yeast models provide advantages due to the extensive characterization of ESC2 in this system. Studies have detailed the effects of various ESC2 mutations on phenotypes like DNA damage sensitivity and sister chromatid cohesion .

  • Complementation Studies: To understand functional conservation, consider complementation experiments where human ESCO2 is expressed in esc2Δ yeast strains to assess functional rescue.

  • Domain-Specific Analysis: When comparing the proteins, focus on conserved domains like the SUMO-like domains in ESC2 and their potential counterparts in ESCO2.

• Function-Based Differentiation:

  • DNA Binding Assays: ESC2 has demonstrated preferential binding to Holliday junctions and replication fork structures . Comparative analysis of DNA binding properties between ESC2 and ESCO2 can help identify functional similarities and differences.

  • Protein Interaction Studies: While ESC2 interacts with the Mus81 complex and Sir2 , determining whether ESCO2 shares these interaction partners can help differentiate their functions.

  • Phenotypic Analysis: Compare phenotypes of ESC2 and ESCO2 deficiency across species. For instance, esc2Δ yeast cells show sensitivity to hydroxyurea and defects in sister chromatid cohesion . Comparing these with ESCO2-deficient human cells can highlight conserved functions.

• Technical Approaches for Differentiation:

  • RT-qPCR with Species-Specific Primers: Design primers that specifically amplify either ESC2 or ESCO2 transcripts.

  • Western Blotting: Use the molecular weight difference between ESC2 and ESCO2 to distinguish them on Western blots.

  • Mass Spectrometry: For definitive identification, use mass spectrometry to identify specific peptides unique to either ESC2 or ESCO2.

• Evolutionary Context Consideration:

  • Phylogenetic Analysis: Construct phylogenetic trees of ESC2/ESCO2 proteins across species to understand evolutionary relationships.

  • Functional Conservation Assessment: Determine which aspects of ESC2 function are conserved in ESCO2 and which represent species-specific adaptations.

What are the most common technical challenges when working with ESC2 antibodies and how can they be addressed?

Researchers working with ESC2 antibodies may encounter several technical challenges that can be addressed through systematic troubleshooting approaches:

• Protein Stability and Detection Issues:

  • Challenge: Research has shown that certain ESC2 fragments, particularly Esc2ΔC (lacking SUMO-like domains), are intrinsically unstable and difficult to detect in crude extracts .

  • Solution:

    • Implement protein enrichment steps through immunoprecipitation before detection

    • Use protease inhibitors to prevent degradation during sample preparation

    • Consider lower incubation temperatures during extraction

    • When studying truncated versions, include SUMO-like domains to enhance stability, as research shows even one SUMO or SUMO-like domain is sufficient for stabilization

• Epitope Masking Due to Protein-Protein Interactions:

  • Challenge: ESC2 interacts with multiple partners, including Sir2 (via its N-terminal domain) and the Mus81 complex (via SUMO-like domains) , which might mask epitopes.

  • Solution:

    • Use multiple antibodies targeting different regions of ESC2

    • Consider mild detergent conditions to partially disrupt protein-protein interactions without denaturing ESC2

    • Implement epitope retrieval techniques for fixed samples

    • Design experimental timing to capture ESC2 before complex formation

• DNA Binding Interference:

  • Challenge: ESC2's DNA binding region (approximately AA154-198) shows high affinity for junction structures , which may interfere with antibody recognition.

  • Solution:

    • Include DNase treatment in sample preparation when appropriate

    • Select antibodies targeting regions not involved in DNA binding

    • For ChIP experiments, optimize crosslinking conditions to preserve both DNA binding and antibody recognition

• Non-specific Signals in Complex Samples:

  • Challenge: In complex biological samples, antibodies may cross-react with similar proteins or SUMO-like domains in other proteins.

  • Solution:

    • Include proper negative controls (esc2Δ samples)

    • Perform competitive blocking with recombinant ESC2 fragments

    • Optimize antibody concentration through titration experiments

    • Consider pre-clearing samples with non-specific immunoglobulins

• Contradictory Results Between Experimental Approaches:

  • Challenge: Different experimental approaches may yield seemingly contradictory results about ESC2 localization or function.

  • Solution:

    • Verify antibody performance in each specific application

    • Consider that different functional pools of ESC2 may exist in cells (research shows ESC2 has multiple roles in silencing and DNA damage tolerance)

    • Implement multiple, complementary detection methods

    • Control for cell cycle stage, as ESC2 functions may vary throughout the cell cycle

How can researchers design experiments to investigate contradictory findings about ESC2's role in DNA repair pathways?

When facing contradictory findings regarding ESC2's role in DNA repair pathways, researchers can implement systematic experimental approaches to resolve discrepancies:

• Genetic Interaction Analysis:

  • Strategy: Create and characterize double mutants of ESC2 with genes in different repair pathways.

  • Implementation: Prior research demonstrated enhanced phenotypes in esc2Δ rrm3Δ double mutants, revealing synthetic interactions between these pathways . Similar approaches can help place ESC2 in specific repair contexts.

  • Analysis: Quantitatively assess the severity of DNA damage sensitivity, growth defects, and accumulation of repair intermediates in single versus double mutants.

  • Expected Outcome: Synergistic interactions suggest parallel pathways, while epistatic interactions suggest function within the same pathway.

• Domain-Specific Functional Analysis:

  • Strategy: Create a panel of ESC2 mutants with alterations in specific domains and assess their impact on various DNA repair functions.

  • Implementation: Express truncated or point-mutated versions of ESC2 in esc2Δ cells and measure complementation of repair defects. Previous research has characterized several functional domains:

    • N-terminal domain (interacts with Sir2)

    • DNA binding region (AA154-198, binds Holliday junctions)

    • SUMO-like domains (interact with Mus81 complex)

  • Analysis: Compare the ability of each mutant to rescue different phenotypes (HU sensitivity, accumulation of SCJs, sister chromatid cohesion defects).

  • Expected Outcome: Different domains may be important for different repair functions, explaining seemingly contradictory findings.

• Temporal Resolution of ESC2 Functions:

  • Strategy: Implement systems for temporal control of ESC2 expression or activity to distinguish early versus late functions in repair pathways.

  • Implementation: Use inducible systems or degron-tagged ESC2 variants that can be rapidly depleted at specific times.

  • Analysis: Assess the impact of ESC2 depletion at different stages of the cell cycle or at different times after DNA damage induction.

  • Expected Outcome: Research has suggested ESC2 has both early and late roles in recombination-mediated damage-bypass . Temporal studies can separate these functions and resolve contradictions.

• Biochemical Reconstitution of Specific Activities:

  • Strategy: Reconstitute specific ESC2 activities in vitro to directly test functional hypotheses without cellular complexity.

  • Implementation: Purify recombinant ESC2 and potential interacting partners (such as the Mus81 complex) to test activities like:

    • DNA binding preference, using EMSA with various DNA structures

    • Enhancement of Mus81 complex nuclease activity

    • Effects on other repair activities

  • Analysis: Compare biochemical activities with cellular phenotypes to identify correlations.

  • Expected Outcome: Direct biochemical evidence can resolve contradictions arising from indirect measurements in complex cellular systems.

• Cell Cycle-Specific Analysis:

  • Strategy: Examine ESC2 functions in synchronized cell populations to determine cell cycle-specific roles.

  • Implementation: Synchronize cells at different cell cycle stages and assess:

    • ESC2 localization and chromatin association

    • Protein-protein interactions, particularly with the Mus81 complex

    • DNA damage sensitivity and repair capacity

  • Analysis: Compare findings across different cell cycle stages.

  • Expected Outcome: Contradictory findings might be explained by cell cycle-specific functions of ESC2, such as its role in resolution of SCJs specifically in G2/M .